Paper34522017
The tangled history of mRNA vaccines.
Dolgin E. Nature, 2021. Cited by 306 papers, by iCite.
Cite this record
ConductScience Library. The tangled history of mRNA vaccines. Papers, record 34522017. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/34522017
- Sources
- 11 sources
- Release
- papers-2026-11-12-0.1.0
Paper
PubMed's record of the paper, with iCite's citation figures. No abstract is shown.
Topics25
NLM's MeSH indexing of the paper, its major topics first.
| MeSH term | Major |
|---|---|
| COVID-19 Vaccines | Major topic |
| Drug Industry | Major topic |
| Research | Major topic |
| Research Personnel | Major topic |
| Vaccines, Synthetic | Major topic |
| Animals | |
| Clinical Trials as Topic | |
| Genetic Therapy | |
| History, 20th Century | |
| History, 21st Century | |
| Humans | |
| Liposomes | |
| Mice | |
| Nanoparticles | |
| Neoplasms | |
| Nobel Prize | |
| Patents as Topic | |
| Pseudouridine | |
| RNA | |
| RNA Stability | |
| Rabbits | |
| Spike Glycoprotein, Coronavirus | |
| Toll-Like Receptors | |
| Vaccines, DNA | |
| mRNA Vaccines |
Source PubMed
References21
The papers the reference list in PubMed's record names, those in our copy of PubMed, in the list's order.
| Order | PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|---|
| 1 | 10602021 | In vivo application of RNA leads to induction of specific cytotoxic T lymphocytes and antibodies. | Eur J Immunol | 2000 | https://conductscience.org/library/papers/10602021 | PubMed |
| 2 | 22908294 | Nonviral delivery of self-amplifying RNA vaccines. | Proc Natl Acad Sci U S A | 2012 | https://conductscience.org/library/papers/22908294 | PubMed |
| 3 | 15835741 | A scalable, extrusion-free method for efficient liposomal encapsulation of plasmid DNA. | Pharm Res | 2005 | https://conductscience.org/library/papers/15835741 | PubMed |
| 4 | 10455412 | Overexpression of urokinase receptor in mammalian cells following administration of the in vitro transcribed encoding mRNA. | Gene Ther | 1999 | https://conductscience.org/library/papers/10455412 | PubMed |
| 5 | 6091052 | Efficient in vitro synthesis of biologically active RNA and RNA hybridization probes from plasmids containing a bacteriophage SP6 promoter. | Nucleic Acids Res | 1984 | https://conductscience.org/library/papers/6091052 | PubMed |
| 6 | 17476302 | Spontaneous cellular uptake of exogenous messenger RNA in vivo is nucleic acid-specific, saturable and ion dependent. | Gene Ther | 2007 | https://conductscience.org/library/papers/17476302 | PubMed |
| 7 | 683336 | Translation of rabbit globin mRNA introduced by liposomes into mouse lymphocytes. | Nature | 1978 | https://conductscience.org/library/papers/683336 | PubMed |
| 8 | 20888316 | Highly efficient reprogramming to pluripotency and directed differentiation of human cells with synthetic modified mRNA. | Cell Stem Cell | 2010 | https://conductscience.org/library/papers/20888316 | PubMed |
| 9 | 33487468 | Proof-of-concept of a low-dose unmodified mRNA-based rabies vaccine formulated with lipid nanoparticles in human volunteers: A phase 1 trial. | Vaccine | 2021 | https://conductscience.org/library/papers/33487468 | PubMed |
| 10 | 34378087 | Safety and immunogenicity of an mRNA-lipid nanoparticle vaccine candidate against SARS-CoV-2 : A phase 1 randomized clinical trial. | Wien Klin Wochenschr | 2021 | https://conductscience.org/library/papers/34378087 | PubMed |
| 11 | 8760800 | Dendritic cells pulsed with RNA are potent antigen-presenting cells in vitro and in vivo. | J Exp Med | 1996 | https://conductscience.org/library/papers/8760800 | PubMed |
| 12 | 16111635 | Suppression of RNA recognition by Toll-like receptors: the impact of nucleoside modification and the evolutionary origin of RNA. | Immunity | 2005 | https://conductscience.org/library/papers/16111635 | PubMed |
| 13 | 14729660 | mRNA is an endogenous ligand for Toll-like receptor 3. | J Biol Chem | 2004 | https://conductscience.org/library/papers/14729660 | PubMed |
| 14 | 7882341 | Characterization of a messenger RNA polynucleotide vaccine vector. | Cancer Res | 1995 | https://conductscience.org/library/papers/7882341 | PubMed |
| 15 | 1690918 | Direct gene transfer into mouse muscle in vivo. | Science | 1990 | https://conductscience.org/library/papers/1690918 | PubMed |
| 16 | 9518670 | Phosphate-enhanced transfection of cationic lipid-complexed mRNA and plasmid DNA. | Biochim Biophys Acta | 1998 | https://conductscience.org/library/papers/9518670 | PubMed |
| 17 | 683335 | Evidence for translation of rabbit globin mRNA after liposome-mediated insertion into a human cell line. | Nature | 1978 | https://conductscience.org/library/papers/683335 | PubMed |
| 18 | 8325342 | Induction of virus-specific cytotoxic T lymphocytes in vivo by liposome-entrapped mRNA. | Eur J Immunol | 1993 | https://conductscience.org/library/papers/8325342 | PubMed |
| 19 | 6207484 | Functional messenger RNAs are produced by SP6 in vitro transcription of cloned cDNAs. | Nucleic Acids Res | 1984 | https://conductscience.org/library/papers/6207484 | PubMed |
| 20 | 1546298 | Reversal of diabetes insipidus in Brattleboro rats: intrahypothalamic injection of vasopressin mRNA. | Science | 1992 | https://conductscience.org/library/papers/1546298 | PubMed |
Cited by237
The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 306 citations.
| PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|
| 42780913 | Codon-dependent translation of N1-ethylpseudouridine-modified mRNA reduces innate immunity while preserving vaccine immunogenicity. | Mol Ther Nucleic Acids | 2026 | https://conductscience.org/library/papers/42780913 | PubMed |
| 42736202 | Astragalus polysaccharides alleviate LPS-induced inflammatory injury in the avian macrophage cell line HD11 via the TLR2/PI3K/AKT/NF-κB signaling pathway. | Poult Sci | 2026 | https://conductscience.org/library/papers/42736202 | PubMed |
| 42719780 | Current landscape and future directions of neoantigen vaccines: A new era of personalized cancer immunotherapy. | Innovation (Camb) | 2026 | https://conductscience.org/library/papers/42719780 | PubMed |
| 42533521 | Characterization of Short Production Cycle and Nongenotoxic mRNA-Based CAR-T Cells Targeting CD19-Positive and CD22-Positive Malignancies. | J Immunol Res | 2026 | https://conductscience.org/library/papers/42533521 | PubMed |
| 42506664 | Beyond PrEP: The Imperative for an HIV Vaccine to End the Epidemic in Africa. | Vaccines (Basel) | 2026 | https://conductscience.org/library/papers/42506664 | PubMed |
| 42505558 | From Pandemic Innovation to Platform Diversification: A Systematic Review of Clinical and Preclinical Development of Non-SARS-CoV-2 mRNA Vaccines. | Diseases | 2026 | https://conductscience.org/library/papers/42505558 | PubMed |
| 42369559 | mRNA vaccines against viral pathogens: molecular design, delivery systems, and clinical applications. | Front Microbiol | 2026 | https://conductscience.org/library/papers/42369559 | PubMed |
| 42236989 | Towards mRNA therapeutics 2.0. | Nat Rev Drug Discov | 2026 | https://conductscience.org/library/papers/42236989 | PubMed |
| 42215480 | Polypeptide-engineered lipid nanoparticles for mRNA delivery with limited immunogenicity. | Nat Commun | 2026 | https://conductscience.org/library/papers/42215480 | PubMed |
| 42152524 | Macrophage Immune Responses in Viral Infections: Functional Plasticity and Therapeutic Targeting. | J Microbiol Biotechnol | 2026 | https://conductscience.org/library/papers/42152524 | PubMed |
| 42100852 | Generation of precise and accurate engineered circRNAs using enzymatic ligation. | Nucleic Acids Res | 2026 | https://conductscience.org/library/papers/42100852 | PubMed |
| 42057181 | Bridging functional bionanomaterials and the clinic: strategic communication as a translational enabler. | J Nanobiotechnology | 2026 | https://conductscience.org/library/papers/42057181 | PubMed |
| 41932444 | A systematic review on vaccine developmental approaches: Evaluating efficacy, and addressing challenges of infectious diseases in the post-COVID-19 era. | Virus Res | 2026 | https://conductscience.org/library/papers/41932444 | PubMed |
| 41920287 | mRNA vaccines in cancer immunotherapy: current progress and perspectives in solid tumors and hematologic malignancies. | MedScience | 2026 | https://conductscience.org/library/papers/41920287 | PubMed |
| 41893758 | Circular RNA as a New Vaccine Platform: Considerations, Challenges, and Perspectives. | Vaccines (Basel) | 2026 | https://conductscience.org/library/papers/41893758 | PubMed |
| 41889911 | Structure-Activity Mapping of Intraperitoneal mRNA-LNPs: Decoupling Tumor and Liver Biodistribution in Pancreatic Cancer. | bioRxiv | 2026 | https://conductscience.org/library/papers/41889911 | PubMed |
| 41881999 | Cancer vaccines and RNA therapeutics: exploring the impact of microRNAs. | NPJ Vaccines | 2026 | https://conductscience.org/library/papers/41881999 | PubMed |
| 41878421 | GenIV vaccines: bridging innovation to equity in neglected tropical diseases. | Front Immunol | 2026 | https://conductscience.org/library/papers/41878421 | PubMed |
| 41809895 | The strategies and advances of mRNA translation booster. | Asian J Pharm Sci | 2025 | https://conductscience.org/library/papers/41809895 | PubMed |
| 41808349 | Respiratory syncytial virus mRNA vaccine-induced immunity and protection against subgroups A and B in mice. | Immunohorizons | 2026 | https://conductscience.org/library/papers/41808349 | PubMed |
Data dates
The date of each source this release read.
- Trials
- 2026-11-12
- Gene search
- 2026-11-11
- Pipelines
- 2026-09-18
None in this release
- Grants
- Trials
- Comments and corrections
- Genes
- Drugs
- Data
Sources 11
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- HGNCCC0
- iCiteCC BY 4.0
- NCBI GenePublic domain (US government)
- NIH RePORTER's grant and paper linksPublic domain
- Open TargetsCC0 1.0
- PMC's ID filePublic domain (US government)
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- HGNCCC0: https://www.genenames.org/about/license/
- iCiteCC BY 4.0
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this paper from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/papers/v1/34522017
GET https://conductscience.org/api/papers/v1/34522017/references?page=2